BRAF and melanoma: In the CheckMate 066 trial, the 5-year overall survival rate was 39% with nivolumab, 17% with dacarbazine, and 38% with dacarbazine and subsequent therapy, including nivolumab in patients with wild-type BRAF advanced melanoma.